- Home
- SHOT vs BOLD Comparison
SHOT vs BOLD Comparison
Compare SHOT & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHOT
- BOLD
- Stock Information
- Founded
- SHOT 2018
- BOLD 2018
- Country
- SHOT United States
- BOLD United States
- Employees
- SHOT N/A
- BOLD N/A
- Industry
- SHOT Biotechnology: Pharmaceutical Preparations
- BOLD
- Sector
- SHOT Health Care
- BOLD
- Exchange
- SHOT Nasdaq
- BOLD Nasdaq
- Market Cap
- SHOT 30.4M
- BOLD 24.4M
- IPO Year
- SHOT 2020
- BOLD 2024
- Fundamental
- Price
- SHOT $0.73
- BOLD $1.19
- Analyst Decision
- SHOT
- BOLD Buy
- Analyst Count
- SHOT 0
- BOLD 3
- Target Price
- SHOT N/A
- BOLD $4.00
- AVG Volume (30 Days)
- SHOT 7.8M
- BOLD 105.5K
- Earning Date
- SHOT 08-13-2025
- BOLD 08-11-2025
- Dividend Yield
- SHOT N/A
- BOLD N/A
- EPS Growth
- SHOT N/A
- BOLD N/A
- EPS
- SHOT N/A
- BOLD N/A
- Revenue
- SHOT $573,336.00
- BOLD N/A
- Revenue This Year
- SHOT N/A
- BOLD N/A
- Revenue Next Year
- SHOT N/A
- BOLD N/A
- P/E Ratio
- SHOT N/A
- BOLD N/A
- Revenue Growth
- SHOT 69.32
- BOLD N/A
- 52 Week Low
- SHOT $0.23
- BOLD $1.00
- 52 Week High
- SHOT $1.77
- BOLD $4.72
- Technical
- Relative Strength Index (RSI)
- SHOT 57.75
- BOLD N/A
- Support Level
- SHOT $0.65
- BOLD N/A
- Resistance Level
- SHOT $1.13
- BOLD N/A
- Average True Range (ATR)
- SHOT 0.15
- BOLD 0.00
- MACD
- SHOT 0.02
- BOLD 0.00
- Stochastic Oscillator
- SHOT 38.00
- BOLD 0.00
About SHOT Safety Shot Inc.
Safety Shot Inc is a wellness and functional beverage company. It is set to launch Safety Shot, the patented beverage that helps people feel faster by reducing blood alcohol content and boosting clarity.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.